By Professor Sallie Pearson

Conference Papers

Pearson S; Srasuebkul P; Harris C; Ward RL; Dobbins TA; Harris C, 2010, 'Trastuzumab treatment outcomes according to concomitant chemotheray regimen: Overall survival of HER2+ metastatic breast cancer patients', in Storm BL; Hasford J; Hennessy S; Park BJ (eds.), Pharmacoepidemiology and Drug Safety, John Wiley & Sons Ltd, Chichester, W Sussex, England, pp. S187 - S187, presented at Pharmacoepidemiology & Therapeutic Risk Management, Brighton, UK, 19 August 2010 - 22 August 2010, http://dx.doi.org/10.1002/pds

Pearson S; Chin M; Ward RL, 2009, 'The Financially Tolerable Dose: A New Concept in Cancer Trial Design', in Storm BL; Hasford J; Hennessy S; Park BJ (eds.), Pharmacoepidemiology and Drug Safety, John Wiley & Sons Ltd, Chichester, W Sussex, England, pp. S173 - S174

Pearson S; Ringland C; Ward RL, 2008, 'Off-label trastuzumab use in Australia: Evidence from the national Herceptin Program for HER-2 positive metastatic breast cancer', in Storm BL; Hasford J; Hennessy S; Park BJ (eds.), Pharmacoepidemiology and Drug Safety, John Wiley & Sons Ltd, Chichester, W Sussex, England, pp. 66 - 66, presented at Pharmacoepidemiology and Drug Safety

Ringland C; Pearson S; Ward RL, 2008, 'Survival of women treated with trastuzumab for HER-2-positive metastatic breast cancer: Estimating outcomes in clinical practice using administrative data', in Storm BL; Hasford J; Hennessy S; Park BJ (eds.), Pharmacoepidemiology and Drug Safety, John Wiley & Sons Ltd, Chichester, W Sussex, England, pp. 436 - 437, presented at Pharmacoepidemiology and Drug Safety

Conference Posters

Gisev N; Degenhardt L; Buckley N; Larney S; Dobbins T; Pearson S, 2017, 'To what extent do data from pharmaceutical claims under-estimate opioid analgesic utilisation in Australia?', Vol. 26, pp. 106 - 106, presented at National Drug and Alcohol Research Centre 2017 Annual Symposium, 03 October 2017 - 04 October 2017

Schaffer AL; buckley N; cairns R; pearson S, 2016, 'Up-Scheduling of Alprazolam to a “Controlled Drug”: Interrupted Time Series Analysis of Its Impact on Benzodiazepine (BZD) Prescribing, Dispensing and Poisonings in Australia.', Dublin, Ireland, Vol. 25, pp. 346 - 347, presented at 32nd International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Dublin, Ireland, 25 August 2016 - 28 August 2016, http://dx.doi.org/10.1002/pds.4070

Ringland C; Pearson S-A; Ward RL, 2008, 'Survival of women treated with trastuzumab for HER-2-positive metastatic breast cancer: Estimating outcomes in clinical practice using administrative data', Vol. 17, pp. S191 - S192, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000258420100436&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Presentations

Bharat C; Gisev N; Hopkins R; Pearson SA; Gillies M; Dobbins T; Larney S; Blythe F; Degenhardt L, 2024, 'Development of opioid use disorder following treatment with opioid analgesics for non-cancer pain relief: an Australian state-wide nested case-control study', presented at 2024 NDARC Annual Research Symposium, Wesley Conference Centre, Sydney NSW, 20 September 2024, https://www.youtube.com/watch?v=SwVO9ONBuE8&t=5295s

Robijn A; Tran DT; Cohen JM; Donald S; Cesta CE; Furu K; Parkin L; Pearson SA; Reutfors J; Zoega H; Zwar N; Havard A, 2024, 'Effectiveness of prescription smoking cessation pharmacotherapies during pregnancy: a multi-national study', presented at 2024 NDARC Annual Research Symposium, Wesley Conference Centre, Sydney NSW, 20 September 2024

Tran D; Varney B; Jones N; Bharat C; Brett J; Oei J; Pearson SA; Degenhardt L; Havard A, 2024, 'Trends in the use of opioid agonist treatment for opioid dependence in pregnancy', presented at 2024 NDARC Annual Research Symposium, Wesley Conference Centre, Sydney NSW, 20 September 2024, https://www.youtube.com/watch?v=Cph4ZrfKiMw&t=1850s

Varney B; Bharat C; Brett J; Degenhardt L; Jones N; Oei J; Pearson SA; Havard A; Tran DT, 2024, 'Use of opioid agonist therapy in pregnancy: Timing of initiation and treatment retention', presented at 2024 NDARC Annual Research Symposium, Wesley Conference Centre, Sydney NSW, 20 September 2024, https://www.youtube.com/watch?v=Cph4ZrfKiMw&t=2664s

Schaffer A; Nassar N; Bruno C; Buckley N; Cairns R; Litchfield M; Paget S; Zoega H; Pearson S, 2021, 'Prescribed Medicine Use in a Nationwide Sample of Australian Children: Extent of Off-Label Use', presented at International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Virtual, 23 August 2021 - 25 August 2021

Schaffer A; Brett J; Buckley N; Pearson S, 2021, 'Trajectories of Pregabalin Use and Their Association with Longitudinal Changes in Opioid and Benzodiazepine Daily Dose', presented at International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Virtual, 23 August 2021 - 25 August 2021

Schaffer A; Cairns R; Brown J; Gisev N; Buckley N; Pearson S, 2020, 'Changes in sales of over‐the‐counter and prescription medicines after rescheduling of codeine to a prescription‐only medicine in Australia', presented at International Conference on Pharmacoepidemiology and Therapeutic Risk Management

Daniels B, 2019, 'Identifying incident cancer cases in medicine dispensing claims: A validation study using Australia’s Pharmaceutical Benefits Scheme (PBS) data', presented at Asian Conference on Pharmacoepidemiology & Therapeutic Risk Management, 11 October 2019 - 13 October 2019

Schaffer A; Buckley N; Pearson S, 2019, 'Unintended Consequences of a National Policy Intervention to Curb Inappropriate Alprazolam Prescribing in Australia', presented at International Conference on Pharmacoepidemiology and Drug Safety, Philadelphia, USA, 24 August 2019 - 28 August 2019, http://dx.doi.org/10.1002/pds.4864

Daniels B; Pearson S, 2019, 'Understanding Treatment Pathways for HER2-Positive Metastatic Breast Cancer (HER2+MBC) Patients: Analysis Using Group-Based Trajectory Models (GBTM)', presented at International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Prague, Czechia, 24 August 2019 - 26 August 2019

Daniels B; Pearson S, 2017, 'Real-world use and outcomes of trastuzumab for HER2+ metastatic breast cancer in Australia: Analysis of the Herceptin Program, 2001 – 2015', presented at San Antonio Breast Cancer Symposium, San Antonio, TX, USA, 06 December 2017 - 10 December 2017

Daniels B; Pearson S, 2017, 'Patterns of care and outcomes for long-term survivors with HER2-positive metastatic breast cancer (HER2+MBC) starting trastuzumab: An Australian whole-of-population cohort study', presented at Clinical Oncology Society of Australia Annual Scientific Meeting, 13 November 2017 - 15 November 2017

Daniels B; Pearson S, 2017, 'Did a policy to ease the prescribing restrictions for lapatinib as second-line HER2-positive metastatic breast cancer increase initiation rates?', presented at International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Montreal, QC, Canada, 26 August 2017 - 28 August 2018

Schaffer AL; Buckley NA; Dobbins TA; Degenhardt L; Larance B; Pearson S-A, 2017, 'Opioid Switching After Introduction of a Tamper-Resistant Oxycodone Formulation in Australia: A Population-Based Study', https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000437103900349&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Daniels B; Pearson S, 2016, 'Real-word use and outcomes of trastuzumab for metastatic breast cancer in Australia: Analysis of the Herceptin Program, 2001 – 2014', presented at Clinical Oncology Society of Australia Annual Scientific Meeting, Gold Coast, QLD, 15 November 2016 - 17 November 2016

Daniels B; Pearson S, 2016, 'Tracking trastuzumab (H) therapy in early- through late-stage HER2-positive breast cancer (HER2+BC) in Australia: A national, retrospective cohort study', presented at International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Dublin, Ireland, 26 August 2016 - 29 August 2016

Schaffer AL; pearson S; buckley N, 2016, 'Does Concordance with Fixed-Dose Combination (FDC) Treatment Guidelines Improve Persistence? An Australian Population Based Cohort Study.', presented at 32nd International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Dublin, Ireland, 25 August 2016 - 28 August 2016, http://dx.doi.org/10.1002/pds.4070

joshi V; adelstein BA; Schaffer AL; srasuebkul P; EoCC Investigators ; dobbins T; pearson S, 2016, 'A Proxy of Cancer Progression in Dispensing Claims: Validation and Performance', presented at 29th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Montreal, Canada, 25 August 2016 - 28 August 2016, http://dx.doi.org/10.1002/pds.3512

Daniels B; Pearson S, 2016, 'Opportunities for post-market surveillance of high cost medicines in Australia: Observing trastuzumab-treated women from early- through late-stage HER2-positive breast cancer (HER2+BC)', presented at International Population Data Linkage Conference, Swansea, Wales, UK, 23 August 2016 - 26 August 2016, http://dx.doi.org/10.23889/ijpds.v1i1.142

Schaffer AL; Buckley NA; Dobbins T; Banks E; Pearson S-A, 2015, 'Time Series Analysis of the Impact of Adverse Media on Statin Dispensing and Discontinuation in Australia'

Vajdic CM; Schaffer A; Dobbins TA; Ward RL; Barrett J; Er CC; Pearson S-A, 2014, 'Health service utilisation and investigations before diagnosis of cancer of unknown primary (CUP): A population-based nested case-control study', presented at 2014 World Cancer Congress, Melbourne, 03 December 2014 - 06 December 2014, http://dx.doi.org/10.1111/ajco.12332

Vajdic CM; Schaffer A; Dobbins TA; Barrett J; Ward RL; Er CC; Pearson S-A, 2014, 'HEALTH SERVICE UTILISATION AND INVESTIGATIONS BEFORE DIAGNOSIS OF CANCER OF UNKNOWN PRIMARY (CUP): A POPULATION-BASED NESTED CASE-CONTROL STUDY', https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344745100020&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Harris C; Daniels B; Ward R; Pearson S-A, 2013, 'DO PHARMACEUTICAL CLAIMS ACCURATELY REFLECT ONCOLOGY PRESCRIBING PRACTICE: EVIDENCE FROM AN AUSTRALIAN HER2+EARLY BREAST CANCER COHORT (HER2EBC)', https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000325868800200&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Schaffer AL; Pearson S-A; Dobbins T; Er C; Meagher NS; Barrett J; Ward RL; Vajdic CM, 2013, 'HEALTH SERVICE USE, TREATMENT PATTERNS, AND SURVIVAL FOR CANCER OF UNKNOWN PRIMARY: A DATA LINKAGE STUDY', https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000325868800129&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Harris C; Pearson S-A; Daniels B; Srasuebkul P; Ward R, 2013, 'HER2 POSITIVE EARLY BREAST CANCER (HER2EBC): AN AUSTRALIAN PATTERN OF CARE STUDY', https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000325868800073&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Stavrou E; Buckley N; Olivier J; Pearson S-A, 2012, 'Futile Drug Use at the End of Life? Continuation of Statins after a Cancer Diagnosis', presented at 28th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Barcelona, Spain, 23 August 2012 - 26 August 2012, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000308131701017&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Lu CY; Srasuebkul P; Drew A; Chen K; Ward R; Pearson S-A, 2011, 'Cardiotoxic Cancer Therapies in Australia: Which Patients Are Assessed for Cardiac Function?', https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000294946600550&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Pearson S; Ringland CL; Ward RL, 2008, 'Off-label trastuzumab use in Australia: Evidence from the national Herceptin Program for HER-2 positive metastatic breast cancer', https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000258420100067&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Abstracts

Wang T; Nguyen L; Tan I; Atkins E; Gnanenthiran S; Falster M; Pearson S-A; Picone D; Rodgers A; Schutte A, 2025, 'EVALUATING THE UPTAKE AND POTENTIAL COST SAVINGS OF A NEW 60-DAY DISPENSING POLICY FOR ANTIHYPERTENSIVE MEDICINES IN AUSTRALIA', in Journal of Hypertension, Ovid Technologies (Wolters Kluwer Health), Vol. 43, pp. e220 - e220, http://dx.doi.org/10.1097/01.hjh.0001117472.84114.43

Ali S; Coory M; Donovan P; Na R; Pandeya N; Pearson S-A; Spilsbury K; Stewart L; Thompson B; Tuesley K; Waterhouse M; Webb P; Jordan S; Neale R, 2023, 'Association between unstable diabetes mellitus and risk of pancreatic cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, MA, Boston, Vol. 84, presented at AACR Special Conference - Pancreatic Cancer, MA, Boston, 27 September 2023 - 30 September 2023, http://dx.doi.org/10.1158/1538-7445.PANCA2023-A009

de Oliveira Costa J; Lin J; Pearson S; Buckley NA; Schaffer A; Falster M, 2023, 'Adherence and persistence to cardiovascular medicines in Australia among people initiating therapy in 2018', in Adherence and persistence to cardiovascular medicines in Australia among people initiating therapy in 2018, presented at 39th International Conference on Pharmacoepidemiology & Therapeutic Risk Management 2023

Lin J; Pearson S; Greenfield J; Park KH; Havard A; Brieger D; Day R; Falster M, 2023, 'Trends in use of sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 analogues (GLP-1a) for cardiovascular risk in Australia (2014-2022)', in Trends in use of sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 analogues (GLP-1a) for cardiovascular risk in Australia (2014-2022), presented at 39th International Conference on Pharmacoepidemiology & Therapeutic Risk Management 2023

Bruno C; Havard A; Gillies M; Coghill D; Brett J; Guastella A; Pearson S-A; Zoega H, 2022, 'Patterns of ADHD medicine use: A population-based study among Australian children and adults (2013-2020)', in PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, WILEY, Vol. 31, pp. 71 - 71, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000859084400136&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Camacho X; Schaffer A; Buckley NA; Pratt N; Henry D; Pearson S-A, 2022, 'Trends in dispensing and utilization of tapentadol in Australia', in PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, WILEY, Vol. 31, pp. 543 - 544, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000859084402283&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Daniels B; Luckett T; Falster MO; Liauw W; Gisev N; Pearson S-A, 2022, 'Understanding opioid use prior to and immediately following cancer diagnosis using group-based trajectory models (GBTM)', in PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, WILEY, Vol. 31, pp. 525 - 526, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000859084402246&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Schaffer AL; Brett J; Buckley NA; Pearson SA, 2022, 'Trajectories of pregabalin use and their association with longitudinal changes in opioid and benzodiazepine use', in Pain, Wolters Kluwer, United States, Vol. 163, pp. E614 - E621, United States, http://dx.doi.org/10.1097/j.pain.0000000000002433

Yuen WS; Leung J; Man N; Chiu V; Gisev N; Livingston M; Degenhardt L; Farrell M; Pearson S-A; Dobbins T; Dunlop AJ; Mattick RP; Peacock A, 2021, 'CHARACTERISTICS OF YOUNG PEOPLE AT INDEX ALCOHOL-RELATED HOSPITAL ADMISSIONS AND EMERGENCY DEPARTMENT PRESENTATIONS IN AUSTRALIA: A RETROSPECTIVE DATA LINKAGE COHORT', in DRUG AND ALCOHOL REVIEW, WILEY, Vol. 40, pp. S154 - S154, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000715073200370&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Costa JDO; Pearson S-A; Elshaug A; van Gool K; Jorm L; Falster M, 2021, 'Rates of low value care in NSW public hospitals: variation between public and private inpatients', in INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, OXFORD UNIV PRESS, Vol. 50, http://dx.doi.org/10.1093/ije/dyab168.195

Bruno C; Havard A; Hanly M; Falster K; Nassar N; Edwards B; Guastella A; Pearson S-A; Zoega H, 2021, 'Children's relative age and medicine treatment for attention-deficit/hyperactivity disorder (ADHD) across Australian jurisdictions with different school enrolment policies', in PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, WILEY, Vol. 30, pp. 166 - 167, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000687807300335&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Daniels B; Pearson S-A; Bruno C; Buckley N; Schaffer A; Jun M; Zoega H, 2021, 'Evaluating the impact of new prescribing restrictions for publicy-subsidised proton pump inhibitors in Australia: An interrupted time series analysis', in PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, WILEY, Vol. 30, pp. 219 - 220, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000687807300446&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Camacho X; Havard A; Zoega H; Wilson M; Gomes T; Vigod S; Pearson S; Henry D, 2020, 'Maternal and Neonatal Outcomes Associated with Psychostimulant Use in Pregnancy', in International Journal of Population Data Science, Swansea University, Vol. 5, http://dx.doi.org/10.23889/ijpds.v5i5.1579

Camacho X; Wilson M; Paterson M; Pearson S; Henry D, 2020, 'Supporting Drug Regulators Through Simple Rapid Cycle Analyses', in International Journal of Population Data Science, Swansea University, Vol. 5, http://dx.doi.org/10.23889/ijpds.v5i5.1581

Falster MO; Buckley NA; Brieger D; Pearson S-A, 2020, 'Antihypertensive polytherapy in Australia: Prevalence of inappropriate combinations, 2013-2018', in PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, WILEY, Vol. 29, pp. 198 - 199

Back to profile page